Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P30968
UPID:
GNRHR_HUMAN
Alternative names:
-
Alternative UPACC:
P30968; O75793; Q14D13; Q92644
Background:
The Gonadotropin-releasing hormone receptor (GnRH-R) plays a pivotal role in the reproductive system. It binds to GnRH, triggering the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through a G-protein-coupled phosphatidylinositol-calcium second messenger system. Its isoform 2 can inhibit GnRH-R signaling, showcasing the receptor's complex regulatory mechanisms.
Therapeutic significance:
GnRH-R's involvement in Hypogonadotropic hypogonadism 7, a condition marked by delayed or absent sexual maturation and low gonadotropin levels, underscores its therapeutic potential. Targeting GnRH-R could lead to novel treatments for reproductive disorders, including those with anosmia or normosmic idiopathic hypogonadotropic hypogonadism (nIHH), by modulating hormone release.